APO Research
Talk to an analyst

APO RESEARCH · REPORT

Meningococcal Disease Treatment

Compare research editions
View pricing & licenses

Selected research

Market Analysis & Forecast

Global Meningococcal Disease Treatment Market Analysis and Forecast 2026-2032

19 December 2025191 pages

Choose your research edition.

Industry ResearchMeningococcal Disease Treatment Industry Research Report 2026122 pages · $2,950 USDIndustry Growth & TrendsGlobal Meningococcal Disease Treatment Industry Growth and Trends Forecast to 2032101 pages · $3,450 USDMarket StructureGlobal Meningococcal Disease Treatment Market by Size, by Type, by Application, by Region, History and Forecast 2021-2032198 pages · $3,950 USDMarket Outlook & Growth OpportunitiesGlobal Meningococcal Disease Treatment Market Outlook and Growth Opportunities 2026193 pages · $4,250 USDMarket Analysis & ForecastGlobal Meningococcal Disease Treatment Market Analysis and Forecast 2026-2032191 pages · $4,950 USD

Market perspective

The global Meningococcal Disease Treatment market is projected to grow from US$ million in 2026 to US$ million by 2032, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.

The North America market for Meningococcal Disease Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Europe market for Meningococcal Disease Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

Read the full market overview

Asia-Pacific market for Meningococcal Disease Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The China market for Meningococcal Disease Treatment is estimated to increase from $ million in 2026 to reach $ million by 2032, at a CAGR of % during the forecast period of 2026 through 2032.

The major global companies of Meningococcal Disease Treatment include Walvax Biotechnology Co.,Ltd., Apeloa Pharmaceutical Co.,Ltd., Novartis, Merck Sharp & Dohme, Beijing Minhai Biological Technology Co.,Ltd., CanSino Biologics Inc., Shandong Jincheng Pharmaceutical Group Co.,ltd., Pfizer and Hebei Hejia Pharmaceutical Technology Group Co., Ltd, etc. In 2025, the world's top three vendors accounted for approximately % of the revenue.

Report Includes

This report presents an overview of global market for Meningococcal Disease Treatment, market size. Analyses of the global market trends, with historic market revenue data for 2021 - 2025, estimates for 2026, and projections of CAGR through 2032.

This report researches the key producers of Meningococcal Disease Treatment, also provides the revenue of main regions and countries. Of the upcoming market potential for Meningococcal Disease Treatment, and key regions or countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.

This report focuses on the Meningococcal Disease Treatment revenue, market share and industry ranking of main manufacturers, data from 2021 to 2026. Identification of the major stakeholders in the global Meningococcal Disease Treatment market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.

This report analyzes the segments data by Type and by Application, revenue, and growth rate, from 2021 to 2032. Evaluation and forecast the market size for Meningococcal Disease Treatment revenue, projected growth trends, production technology, application and end-user industry.

Meningococcal Disease Treatment Segment by Company

Walvax Biotechnology Co.,Ltd.

Apeloa Pharmaceutical Co.,Ltd.

Novartis

Merck Sharp & Dohme

Beijing Minhai Biological Technology Co.,Ltd.

CanSino Biologics Inc.

Shandong Jincheng Pharmaceutical Group Co.,ltd.

Pfizer

Hebei Hejia Pharmaceutical Technology Group Co., Ltd

GlaxoSmithKline

Chengdu Institute of Biology

Sanofi Pasteur

Meningococcal Disease Treatment Segment by Type

Antibiotics

Vaccines

Meningococcal Disease Treatment Segment by Application

Hospitals

Drugstores

Others

Meningococcal Disease Treatment Segment by Region

North America

United States

Canada

Europe

Germany

France

U.K.

Italy

Netherlands

Nordic Countries

Asia-Pacific

China

Japan

South Korea

India

Australia

China Taiwan

Southeast Asia

South America

Mexico

Brazil

Argentina

Middle East & Africa

Turkey

Saudi Arabia

UAE

Study Objectives

1. To analyze and research the global status and future forecast, involving growth rate (CAGR), market share, historical and forecast.

2. To present the key players, revenue, market share, and Recent Developments.

3. To split the breakdown data by regions, type, manufacturers, and Application.

4. To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints, and risks.

5. To identify significant trends, drivers, influence factors in global and regions.

6. To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

Reasons to Buy This Report

1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Meningococcal Disease Treatment market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.

2. This report will help stakeholders to understand the global industry status and trends of Meningococcal Disease Treatment and provides them with information on key market drivers, restraints, challenges, and opportunities.

3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in market size), competitor ecosystem, new product development, expansion, and acquisition.

4. This report stays updated with novel technology integration, features, and the latest developments in the market.

5. This report helps stakeholders to gain insights into which regions to target globally.

6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Meningococcal Disease Treatment.

7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.

Chapter Outline

Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.

Chapter 2: Introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by manufacturers in the industry, and the analysis of relevant policies in the industry.

Chapter 3: Revenue of Meningococcal Disease Treatment in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.

Chapter 4: Detailed analysis of Meningococcal Disease Treatment company competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.

Chapter 5: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.

Chapter 6: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.

Chapter 7: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Meningococcal Disease Treatment revenue, gross margin, and recent development, etc.

Chapter 8: North America by type, by application and by country, revenue for each segment.

Chapter 9: Europe by type, by application and by country, revenue for each segment.

Chapter 10: China type, by application, revenue for each segment.

Chapter 11: Asia (excluding China) type, by application and by region, revenue for each segment.

Chapter 12: South America, Middle East and Africa by type, by application and by country, revenue for each segment.

Chapter 13: The main concluding insights of the report.

More report detail

Tables and figures
List of Tables Table 1. Global Meningococcal Disease Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Table 2. Antibiotics Major Player Table 3. Vaccines Major Player Table 4. Global Meningococcal Disease Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Table 5. Hospitals Major Player Table 6. Drugstores Major Player Table 7. Others Major Player Table 8. Meningococcal Disease Treatment Industry Trends Table 9. Meningococcal Disease Treatment Industry Drivers Table 10. Meningococcal Disease Treatment Industry Opportunities and Challenges Table 11. Meningococcal Disease Treatment Industry Restraints Table 12. Global Meningococcal Disease Treatment Market Size Growth Rate (CAGR) by Region (US$ Million): 2021 VS 2025 VS 2032 Table 13. Global Meningococcal Disease Treatment Market Size by Region (2021-2026) & (US$ Million) Table 14. Global Meningococcal Disease Treatment Market Share by Region (2021-2026) Table 15. Global Meningococcal Disease Treatment Market Size by Region (2027-2032) & (US$ Million) Table 16. Global Meningococcal Disease Treatment Market Share by Region (2027-2032) Table 17. Global Meningococcal Disease Treatment Revenue by Players (US$ Million) & (2021-2026) Table 18. Global Meningococcal Disease Treatment Revenue Market Share by Players (2021-2026) Table 19. Global Meningococcal Disease Treatment Key Players Ranking, 2024 VS 2025 VS 2026 Table 20. Global Meningococcal Disease Treatment Key Players Headquarters & Area Served Table 21. Global Meningococcal Disease Treatment Players, Product Type & Application Table 22. Global Meningococcal Disease Treatment Players Establishment Date Table 23. Global Players Market Concentration Ratio (CR5 and HHI) Table 24. Global Meningococcal Disease Treatment by Players Type (Tier 1, Tier 2, and Tier 3) & (Based on the Revenue of 2025) Table 25. Global Meningococcal Disease Treatment Revenue by Type 2021 VS 2025 VS 2032 (US$ Million) Table 26. Global Meningococcal Disease Treatment Revenue by Type (2021-2026) & (US$ Million) Table 27. Global Meningococcal Disease Treatment Revenue by Type (2027-2032) & (US$ Million) Table 28. Global Meningococcal Disease Treatment Revenue Market Share by Type (2021-2026) Table 29. Global Meningococcal Disease Treatment Revenue Market Share by Type (2027-2032) Table 30. Global Meningococcal Disease Treatment Revenue by Application 2021 VS 2025 VS 2032 (US$ Million) Table 31. Global Meningococcal Disease Treatment Revenue by Application (2021-2026) & (US$ Million) Table 32. Global Meningococcal Disease Treatment Revenue by Application (2027-2032) & (US$ Million) Table 33. Global Meningococcal Disease Treatment Revenue Market Share by Application (2021-2026) Table 34. Global Meningococcal Disease Treatment Revenue Market Share by Application (2027-2032) Table 35. Walvax Biotechnology Co.,Ltd. Company Information Table 36. Walvax Biotechnology Co.,Ltd. Business Overview Table 37. Walvax Biotechnology Co.,Ltd. Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 38. Walvax Biotechnology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio Table 39. Walvax Biotechnology Co.,Ltd. Recent Development Table 40. Apeloa Pharmaceutical Co.,Ltd. Company Information Table 41. Apeloa Pharmaceutical Co.,Ltd. Business Overview Table 42. Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 43. Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Treatment Product Portfolio Table 44. Apeloa Pharmaceutical Co.,Ltd. Recent Development Table 45. Novartis Company Information Table 46. Novartis Business Overview Table 47. Novartis Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 48. Novartis Meningococcal Disease Treatment Product Portfolio Table 49. Novartis Recent Development Table 50. Merck Sharp & Dohme Company Information Table 51. Merck Sharp & Dohme Business Overview Table 52. Merck Sharp & Dohme Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 53. Merck Sharp & Dohme Meningococcal Disease Treatment Product Portfolio Table 54. Merck Sharp & Dohme Recent Development Table 55. Beijing Minhai Biological Technology Co.,Ltd. Company Information Table 56. Beijing Minhai Biological Technology Co.,Ltd. Business Overview Table 57. Beijing Minhai Biological Technology Co.,Ltd. Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 58. Beijing Minhai Biological Technology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio Table 59. Beijing Minhai Biological Technology Co.,Ltd. Recent Development Table 60. CanSino Biologics Inc. Company Information Table 61. CanSino Biologics Inc. Business Overview Table 62. CanSino Biologics Inc. Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 63. CanSino Biologics Inc. Meningococcal Disease Treatment Product Portfolio Table 64. CanSino Biologics Inc. Recent Development Table 65. Shandong Jincheng Pharmaceutical Group Co.,ltd. Company Information Table 66. Shandong Jincheng Pharmaceutical Group Co.,ltd. Business Overview Table 67. Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 68. Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Treatment Product Portfolio Table 69. Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Development Table 70. Pfizer Company Information Table 71. Pfizer Business Overview Table 72. Pfizer Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 73. Pfizer Meningococcal Disease Treatment Product Portfolio Table 74. Pfizer Recent Development Table 75. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Company Information Table 76. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Business Overview Table 77. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 78. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Treatment Product Portfolio Table 79. Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Development Table 80. GlaxoSmithKline Company Information Table 81. GlaxoSmithKline Business Overview Table 82. GlaxoSmithKline Meningococcal Disease Treatment Revenue and Gross Margin (US$ Million) & (2021-2026) Table 83. GlaxoSmithKline Meningococcal Disease Treatment Product Portfolio Table 84. GlaxoSmithKline Recent Development Table 85. Chengdu Institute of Biology Company Information Table 86. Chengdu Institute of Biology Business Overview Table 87. Chengdu Institute of Biology Meningococcal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 88. Chengdu Institute of Biology Meningococcal Disease Treatment Product Portfolio Table 89. Chengdu Institute of Biology Recent Development Table 90. Sanofi Pasteur Company Information Table 91. Sanofi Pasteur Business Overview Table 92. Sanofi Pasteur Meningococcal Disease Treatment Sales (K Units), Revenue (US$ Million), Price (US$/Unit) and Gross Margin (2021-2026) Table 93. Sanofi Pasteur Meningococcal Disease Treatment Product Portfolio Table 94. Sanofi Pasteur Recent Development Table 95. North America Meningococcal Disease Treatment Revenue by Type (2021-2026) & (US$ Million) Table 96. North America Meningococcal Disease Treatment Revenue by Type (2027-2032) & (US$ Million) Table 97. North America Meningococcal Disease Treatment Revenue by Application (2021-2026) & (US$ Million) Table 98. North America Meningococcal Disease Treatment Revenue by Application (2027-2032) & (US$ Million) Table 99. North America Meningococcal Disease Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 100. North America Meningococcal Disease Treatment Revenue by Country (2021-2026) & (US$ Million) Table 101. North America Meningococcal Disease Treatment Revenue by Country (US$ Million) & (2027-2032) Table 102. Europe Meningococcal Disease Treatment Revenue by Type (2021-2026) & (US$ Million) Table 103. Europe Meningococcal Disease Treatment Revenue by Type (2027-2032) & (US$ Million) Table 104. Europe Meningococcal Disease Treatment Revenue by Application (2021-2026) & (US$ Million) Table 105. Europe Meningococcal Disease Treatment Revenue by Application (2027-2032) & (US$ Million) Table 106. Europe Meningococcal Disease Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 107. Europe Meningococcal Disease Treatment Revenue by Country (2021-2026) & (US$ Million) Table 108. Europe Meningococcal Disease Treatment Revenue by Country (US$ Million) & (2027-2032) Table 109. China Meningococcal Disease Treatment Revenue by Type (2021-2026) & (US$ Million) Table 110. China Meningococcal Disease Treatment Revenue by Type (2027-2032) & (US$ Million) Table 111. China Meningococcal Disease Treatment Revenue by Application (2021-2026) & (US$ Million) Table 112. China Meningococcal Disease Treatment Revenue by Application (2027-2032) & (US$ Million) Table 113. Asia Meningococcal Disease Treatment Revenue by Type (2021-2026) & (US$ Million) Table 114. Asia Meningococcal Disease Treatment Revenue by Type (2027-2032) & (US$ Million) Table 115. Asia Meningococcal Disease Treatment Revenue by Application (2021-2026) & (US$ Million) Table 116. Asia Meningococcal Disease Treatment Revenue by Application (2027-2032) & (US$ Million) Table 117. Asia Meningococcal Disease Treatment Revenue by Region (2021 VS 2025 VS 2032) & (US$ Million) Table 118. Asia Meningococcal Disease Treatment Revenue by Region (US$ Million) & (2021-2026) Table 119. Asia Meningococcal Disease Treatment Revenue by Region (US$ Million) & (2027-2032) Table 120. SAMEA Meningococcal Disease Treatment Revenue by Type (2021-2026) & (US$ Million) Table 121. SAMEA Meningococcal Disease Treatment Revenue by Type (2027-2032) & (US$ Million) Table 122. SAMEA Meningococcal Disease Treatment Revenue by Application (2021-2026) & (US$ Million) Table 123. SAMEA Meningococcal Disease Treatment Revenue by Application (2027-2032) & (US$ Million) Table 124. SAMEA Meningococcal Disease Treatment Revenue by Country (2021 VS 2025 VS 2032) & (US$ Million) Table 125. SAMEA Meningococcal Disease Treatment Revenue by Country (2021-2026) & (US$ Million) Table 126. SAMEA Meningococcal Disease Treatment Revenue by Country (US$ Million) & (2027-2032) Table 127. Research Programs/Design for This Report Table 128. Authors List of This Report Table 129. Secondary Sources Table 130. Primary Sources List of Figures Figure 1. Meningococcal Disease Treatment Image Figure 2. Global Meningococcal Disease Treatment Market Size Growth Rate by Type (US$ Million), 2021 VS 2025 VS 2032 Figure 3. Global Meningococcal Disease Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 4. Antibiotics Image Figure 5. Vaccines Image Figure 6. Global Meningococcal Disease Treatment Market Size Growth Rate by Application (US$ Million), 2021 VS 2025 VS 2032 Figure 7. Global Meningococcal Disease Treatment Market Size Share 2021 VS 2025 VS 2032 Figure 8. Hospitals Image Figure 9. Drugstores Image Figure 10. Others Image Figure 11. Global Meningococcal Disease Treatment Market Size (US$ Million) & (2021-2032) Figure 12. Global Meningococcal Disease Treatment Market Size, (US$ Million), 2021 VS 2025 VS 2032 Figure 13. Global Meningococcal Disease Treatment Market Share by Region: 2021 VS 2025 VS 2032 Figure 14. Global Meningococcal Disease Treatment Players Revenue Share Top 10 and Top 5 in 2025 Figure 15. Players Type (Tier 1, Tier 2, and Tier 3): 2021 VS 2025 Figure 16. Global Meningococcal Disease Treatment Revenue by Type (2021 VS 2025 VS 2032) & (US$ Million) Figure 17. Global Meningococcal Disease Treatment Revenue Market Share 2021 VS 2025 VS 2032 Figure 18. Global Meningococcal Disease Treatment Revenue Market Share by Type (2021-2032) Figure 19. Global Meningococcal Disease Treatment Revenue by Application (2021 VS 2025 VS 2032) & (US$ Million) Figure 20. Global Meningococcal Disease Treatment Revenue Market Share by Application (2021 VS 2025 VS 2032) Figure 21. Global Meningococcal Disease Treatment Revenue Market Share by Application (2021-2032) Figure 22. North America Meningococcal Disease Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 23. North America Meningococcal Disease Treatment Revenue Share by Type (2021-2032) Figure 24. North America Meningococcal Disease Treatment Revenue Share by Application (2021-2032) Figure 25. North America Meningococcal Disease Treatment Revenue Share by Country (2021-2032) Figure 26. United States Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 27. Canada Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 28. Mexico Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 29. Europe Meningococcal Disease Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 30. Europe Meningococcal Disease Treatment Revenue Share by Type (2021-2032) Figure 31. Europe Meningococcal Disease Treatment Revenue Share by Application (2021-2032) Figure 32. Europe Meningococcal Disease Treatment Revenue Share by Country (2021-2032) Figure 33. Germany Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 34. France Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 35. U.K. Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 36. Italy Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 37. Spain Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 38. Russia Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 39. Netherlands Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 40. Nordic Countries Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 41. China Meningococcal Disease Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 42. China Meningococcal Disease Treatment Revenue Share by Type (2021-2032) Figure 43. China Meningococcal Disease Treatment Revenue Share by Application (2021-2032) Figure 44. Asia Meningococcal Disease Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 45. Asia Meningococcal Disease Treatment Revenue Share by Type (2021-2032) Figure 46. Asia Meningococcal Disease Treatment Revenue Share by Application (2021-2032) Figure 47. Asia Meningococcal Disease Treatment Revenue Share by Region (2021-2032) Figure 48. Japan Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 49. South Korea Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 50. India Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 51. Australia Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 52. Taiwan Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 53. Southeast Asia Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 54. SAMEA Meningococcal Disease Treatment Revenue YoY Growth (2021-2032) & (US$ Million) Figure 55. SAMEA Meningococcal Disease Treatment Revenue Share by Type (2021-2032) Figure 56. SAMEA Meningococcal Disease Treatment Revenue Share by Application (2021-2032) Figure 57. SAMEA Meningococcal Disease Treatment Revenue Share by Country (2021-2032) Figure 58. Brazil Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 59. Argentina Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 60. Chile Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 61. Colombia Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 62. Peru Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 63. Saudi Arabia Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 64. Israel Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 65. UAE Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 66. Turkey Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 67. Iran Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 68. Egypt Meningococcal Disease Treatment Revenue YoY Growth (US$ Million) & (2021-2032) Figure 69. Years Considered Figure 70. Research Process Figure 71. Key Executives Interviewed

Scope & coverage.

Types
  • Antibiotics
  • Vaccines
Applications
  • Hospitals
  • Drugstores
  • Others
Companies covered
  • Walvax Biotechnology Co.,Ltd.
  • Apeloa Pharmaceutical Co.,Ltd.
  • Novartis
  • Merck Sharp & Dohme
  • Beijing Minhai Biological Technology Co.,Ltd.
  • CanSino Biologics Inc.
  • Shandong Jincheng Pharmaceutical Group Co.,ltd.
  • Pfizer
  • Hebei Hejia Pharmaceutical Technology Group Co., Ltd
  • GlaxoSmithKline
  • Chengdu Institute of Biology
  • Sanofi Pasteur

Inside the report.

1 Market Overview
  1. 1.1 Product Definition
  2. 1.2 Meningococcal Disease Treatment Market by Type
  3. 1.2.1 Global Meningococcal Disease Treatment Market Size by Type, 2021 VS 2025 VS 2032
  4. 1.2.2 Antibiotics
  5. 1.2.3 Vaccines
  6. 1.3 Meningococcal Disease Treatment Market by Application
  7. 1.3.1 Global Meningococcal Disease Treatment Market Size by Application, 2021 VS 2025 VS 2032
  8. 1.3.2 Hospitals
  9. 1.3.3 Drugstores
  10. 1.3.4 Others
  11. 1.4 Assumptions and Limitations
  12. 1.5 Study Goals and Objectives
2 Meningococcal Disease Treatment Market Dynamics
  1. 2.1 Meningococcal Disease Treatment Industry Trends
  2. 2.2 Meningococcal Disease Treatment Industry Drivers
  3. 2.3 Meningococcal Disease Treatment Industry Opportunities and Challenges
  4. 2.4 Meningococcal Disease Treatment Industry Restraints
3 Global Growth Perspective
  1. 3.1 Global Meningococcal Disease Treatment Market Perspective (2021-2032)
  2. 3.2 Global Meningococcal Disease Treatment Growth Trends by Region
  3. 3.2.1 Global Meningococcal Disease Treatment Market Size by Region: 2021 VS 2025 VS 2032
  4. 3.2.2 Global Meningococcal Disease Treatment Market Size by Region (2021-2026)
  5. 3.2.3 Global Meningococcal Disease Treatment Market Size by Region (2027-2032)
4 Competitive Landscape by Players
  1. 4.1 Global Meningococcal Disease Treatment Revenue by Players
  2. 4.1.1 Global Meningococcal Disease Treatment Revenue by Players (2021-2026)
  3. 4.1.2 Global Meningococcal Disease Treatment Revenue Market Share by Players (2021-2026)
  4. 4.1.3 Global Meningococcal Disease Treatment Players Revenue Share Top 10 and Top 5 in 2025
  5. 4.2 Global Meningococcal Disease Treatment Key Players Ranking, 2024 VS 2025 VS 2026
  6. 4.3 Global Meningococcal Disease Treatment Key Players Headquarters & Area Served
  7. 4.4 Global Meningococcal Disease Treatment Players, Product Type & Application
  8. 4.5 Global Meningococcal Disease Treatment Players Establishment Date
  9. 4.6 Market Competitive Analysis
  10. 4.6.1 Global Meningococcal Disease Treatment Market CR5 and HHI
  11. 4.6.3 2025 Meningococcal Disease Treatment Tier 1, Tier 2, and Tier 3
5 Meningococcal Disease Treatment Market Size by Type
  1. 5.1 Global Meningococcal Disease Treatment Revenue by Type (2021 VS 2025 VS 2032)
  2. 5.2 Global Meningococcal Disease Treatment Revenue by Type (2021-2032)
  3. 5.3 Global Meningococcal Disease Treatment Revenue Market Share by Type (2021-2032)
6 Meningococcal Disease Treatment Market Size by Application
  1. 6.1 Global Meningococcal Disease Treatment Revenue by Application (2021 VS 2025 VS 2032)
  2. 6.2 Global Meningococcal Disease Treatment Revenue by Application (2021-2032)
  3. 6.3 Global Meningococcal Disease Treatment Revenue Market Share by Application (2021-2032)
7 Company Profiles
  1. 7.1 Walvax Biotechnology Co.,Ltd.
  2. 7.1.1 Walvax Biotechnology Co.,Ltd. Company Information
  3. 7.1.2 Walvax Biotechnology Co.,Ltd. Business Overview
  4. 7.1.3 Walvax Biotechnology Co.,Ltd. Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  5. 7.1.4 Walvax Biotechnology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio
  6. 7.1.5 Walvax Biotechnology Co.,Ltd. Recent Developments
  7. 7.2 Apeloa Pharmaceutical Co.,Ltd.
  8. 7.2.1 Apeloa Pharmaceutical Co.,Ltd. Company Information
  9. 7.2.2 Apeloa Pharmaceutical Co.,Ltd. Business Overview
  10. 7.2.3 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  11. 7.2.4 Apeloa Pharmaceutical Co.,Ltd. Meningococcal Disease Treatment Product Portfolio
  12. 7.2.5 Apeloa Pharmaceutical Co.,Ltd. Recent Developments
  13. 7.3 Novartis
  14. 7.3.1 Novartis Company Information
  15. 7.3.2 Novartis Business Overview
  16. 7.3.3 Novartis Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  17. 7.3.4 Novartis Meningococcal Disease Treatment Product Portfolio
  18. 7.3.5 Novartis Recent Developments
  19. 7.4 Merck Sharp & Dohme
  20. 7.4.1 Merck Sharp & Dohme Company Information
  21. 7.4.2 Merck Sharp & Dohme Business Overview
  22. 7.4.3 Merck Sharp & Dohme Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  23. 7.4.4 Merck Sharp & Dohme Meningococcal Disease Treatment Product Portfolio
  24. 7.4.5 Merck Sharp & Dohme Recent Developments
  25. 7.5 Beijing Minhai Biological Technology Co.,Ltd.
  26. 7.5.1 Beijing Minhai Biological Technology Co.,Ltd. Company Information
  27. 7.5.2 Beijing Minhai Biological Technology Co.,Ltd. Business Overview
  28. 7.5.3 Beijing Minhai Biological Technology Co.,Ltd. Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  29. 7.5.4 Beijing Minhai Biological Technology Co.,Ltd. Meningococcal Disease Treatment Product Portfolio
  30. 7.5.5 Beijing Minhai Biological Technology Co.,Ltd. Recent Developments
  31. 7.6 CanSino Biologics Inc.
  32. 7.6.1 CanSino Biologics Inc. Company Information
  33. 7.6.2 CanSino Biologics Inc. Business Overview
  34. 7.6.3 CanSino Biologics Inc. Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  35. 7.6.4 CanSino Biologics Inc. Meningococcal Disease Treatment Product Portfolio
  36. 7.6.5 CanSino Biologics Inc. Recent Developments
  37. 7.7 Shandong Jincheng Pharmaceutical Group Co.,ltd.
  38. 7.7.1 Shandong Jincheng Pharmaceutical Group Co.,ltd. Company Information
  39. 7.7.2 Shandong Jincheng Pharmaceutical Group Co.,ltd. Business Overview
  40. 7.7.3 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  41. 7.7.4 Shandong Jincheng Pharmaceutical Group Co.,ltd. Meningococcal Disease Treatment Product Portfolio
  42. 7.7.5 Shandong Jincheng Pharmaceutical Group Co.,ltd. Recent Developments
  43. 7.8 Pfizer
  44. 7.8.1 Pfizer Company Information
  45. 7.8.2 Pfizer Business Overview
  46. 7.8.3 Pfizer Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  47. 7.8.4 Pfizer Meningococcal Disease Treatment Product Portfolio
  48. 7.8.5 Pfizer Recent Developments
  49. 7.9 Hebei Hejia Pharmaceutical Technology Group Co., Ltd
  50. 7.9.1 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Company Information
  51. 7.9.2 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Business Overview
  52. 7.9.3 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  53. 7.9.4 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Meningococcal Disease Treatment Product Portfolio
  54. 7.9.5 Hebei Hejia Pharmaceutical Technology Group Co., Ltd Recent Developments
  55. 7.10 GlaxoSmithKline
  56. 7.10.1 GlaxoSmithKline Company Information
  57. 7.10.2 GlaxoSmithKline Business Overview
  58. 7.10.3 GlaxoSmithKline Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  59. 7.10.4 GlaxoSmithKline Meningococcal Disease Treatment Product Portfolio
  60. 7.10.5 GlaxoSmithKline Recent Developments
  61. 7.11 Chengdu Institute of Biology
  62. 7.11.1 Chengdu Institute of Biology Company Information
  63. 7.11.2 Chengdu Institute of Biology Business Overview
  64. 7.11.3 Chengdu Institute of Biology Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  65. 7.11.4 Chengdu Institute of Biology Meningococcal Disease Treatment Product Portfolio
  66. 7.11.5 Chengdu Institute of Biology Recent Developments
  67. 7.12 Sanofi Pasteur
  68. 7.12.1 Sanofi Pasteur Company Information
  69. 7.12.2 Sanofi Pasteur Business Overview
  70. 7.12.3 Sanofi Pasteur Meningococcal Disease Treatment Revenue and Gross Margin (2021-2026)
  71. 7.12.4 Sanofi Pasteur Meningococcal Disease Treatment Product Portfolio
  72. 7.12.5 Sanofi Pasteur Recent Developments
8 North America
  1. 8.1 North America Meningococcal Disease Treatment Revenue (2021-2032)
  2. 8.2 North America Meningococcal Disease Treatment Revenue by Type (2021-2032)
  3. 8.2.1 North America Meningococcal Disease Treatment Revenue by Type (2021-2026)
  4. 8.2.2 North America Meningococcal Disease Treatment Revenue by Type (2027-2032)
  5. 8.3 North America Meningococcal Disease Treatment Revenue Share by Type (2021-2032)
  6. 8.4 North America Meningococcal Disease Treatment Revenue by Application (2021-2032)
  7. 8.4.1 North America Meningococcal Disease Treatment Revenue by Application (2021-2026)
  8. 8.4.2 North America Meningococcal Disease Treatment Revenue by Application (2027-2032)
  9. 8.5 North America Meningococcal Disease Treatment Revenue Share by Application (2021-2032)
  10. 8.6 North America Meningococcal Disease Treatment Revenue by Country
  11. 8.6.1 North America Meningococcal Disease Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 8.6.2 North America Meningococcal Disease Treatment Revenue by Country (2021-2026)
  13. 8.6.3 North America Meningococcal Disease Treatment Revenue by Country (2027-2032)
  14. 8.6.4 United States
  15. 8.6.5 Canada
9 Europe
  1. 9.1 Europe Meningococcal Disease Treatment Revenue (2021-2032)
  2. 9.2 Europe Meningococcal Disease Treatment Revenue by Type (2021-2032)
  3. 9.2.1 Europe Meningococcal Disease Treatment Revenue by Type (2021-2026)
  4. 9.2.2 Europe Meningococcal Disease Treatment Revenue by Type (2027-2032)
  5. 9.3 Europe Meningococcal Disease Treatment Revenue Share by Type (2021-2032)
  6. 9.4 Europe Meningococcal Disease Treatment Revenue by Application (2021-2032)
  7. 9.4.1 Europe Meningococcal Disease Treatment Revenue by Application (2021-2026)
  8. 9.4.2 Europe Meningococcal Disease Treatment Revenue by Application (2027-2032)
  9. 9.5 Europe Meningococcal Disease Treatment Revenue Share by Application (2021-2032)
  10. 9.6 Europe Meningococcal Disease Treatment Revenue by Country
  11. 9.6.1 Europe Meningococcal Disease Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 9.6.2 Europe Meningococcal Disease Treatment Revenue by Country (2021-2026)
  13. 9.6.3 Europe Meningococcal Disease Treatment Revenue by Country (2027-2032)
  14. 9.6.4 Germany
  15. 9.6.5 France
  16. 9.6.6 U.K.
  17. 9.6.7 Italy
  18. 9.6.8 Netherlands
  19. 9.6.9 Nordic Countries
10 China
  1. 10.1 China Meningococcal Disease Treatment Revenue (2021-2032)
  2. 10.2 China Meningococcal Disease Treatment Revenue by Type (2021-2032)
  3. 10.2.1 China Meningococcal Disease Treatment Revenue by Type (2021-2026)
  4. 10.2.2 China Meningococcal Disease Treatment Revenue by Type (2027-2032)
  5. 10.3 China Meningococcal Disease Treatment Revenue Share by Type (2021-2032)
  6. 10.4 China Meningococcal Disease Treatment Revenue by Application (2021-2032)
  7. 10.4.1 China Meningococcal Disease Treatment Revenue by Application (2021-2026)
  8. 10.4.2 China Meningococcal Disease Treatment Revenue by Application (2027-2032)
  9. 10.5 China Meningococcal Disease Treatment Revenue Share by Application (2021-2032)
11 Asia (Excluding China)
  1. 11.1 Asia Meningococcal Disease Treatment Revenue (2021-2032)
  2. 11.2 Asia Meningococcal Disease Treatment Revenue by Type (2021-2032)
  3. 11.2.1 Asia Meningococcal Disease Treatment Revenue by Type (2021-2026)
  4. 11.2.2 Asia Meningococcal Disease Treatment Revenue by Type (2027-2032)
  5. 11.3 Asia Meningococcal Disease Treatment Revenue Share by Type (2021-2032)
  6. 11.4 Asia Meningococcal Disease Treatment Revenue by Application (2021-2032)
  7. 11.4.1 Asia Meningococcal Disease Treatment Revenue by Application (2021-2026)
  8. 11.4.2 Asia Meningococcal Disease Treatment Revenue by Application (2027-2032)
  9. 11.5 Asia Meningococcal Disease Treatment Revenue Share by Application (2021-2032)
  10. 11.6 Asia Meningococcal Disease Treatment Revenue by Country
  11. 11.6.1 Asia Meningococcal Disease Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 11.6.2 Asia Meningococcal Disease Treatment Revenue by Country (2021-2026)
  13. 11.6.3 Asia Meningococcal Disease Treatment Revenue by Country (2027-2032)
  14. 11.6.4 Japan
  15. 11.6.5 South Korea
  16. 11.6.6 India
  17. 11.6.7 Australia
  18. 11.6.8 Taiwan
  19. 11.6.9 Southeast Asia
12 South America, Middle East and Africa
  1. 12.1 SAMEA Meningococcal Disease Treatment Revenue (2021-2032)
  2. 12.2 SAMEA Meningococcal Disease Treatment Revenue by Type (2021-2032)
  3. 12.2.1 SAMEA Meningococcal Disease Treatment Revenue by Type (2021-2026)
  4. 12.2.2 SAMEA Meningococcal Disease Treatment Revenue by Type (2027-2032)
  5. 12.3 SAMEA Meningococcal Disease Treatment Revenue Share by Type (2021-2032)
  6. 12.4 SAMEA Meningococcal Disease Treatment Revenue by Application (2021-2032)
  7. 12.4.1 SAMEA Meningococcal Disease Treatment Revenue by Application (2021-2026)
  8. 12.4.2 SAMEA Meningococcal Disease Treatment Revenue by Application (2027-2032)
  9. 12.5 SAMEA Meningococcal Disease Treatment Revenue Share by Application (2021-2032)
  10. 12.6 SAMEA Meningococcal Disease Treatment Revenue by Country
  11. 12.6.1 SAMEA Meningococcal Disease Treatment Revenue by Country (2021 VS 2025 VS 2032)
  12. 12.6.2 SAMEA Meningococcal Disease Treatment Revenue by Country (2021-2026)
  13. 12.6.3 SAMEA Meningococcal Disease Treatment Revenue by Country (2027-2032)
  14. 12.6.4 Brazil
  15. 12.6.5 Argentina
  16. 12.6.6 Chile
  17. 12.6.7 Colombia
  18. 12.6.8 Peru
  19. 12.6.9 Saudi Arabia
  20. 12.6.10 Israel
  21. 12.6.11 UAE
  22. 12.6.12 Turkey
  23. 12.6.13 Iran
  24. 12.6.14 Egypt
13 Concluding Insights
    14 Appendix
    1. 14.1 Reasons for Doing This Study
    2. 14.2 Research Methodology
    3. 14.3 Research Process
    4. 14.4 Authors List of This Report
    5. 14.5 Data Source
    6. 14.5.1 Secondary Sources
    7. 14.5.2 Primary Sources

    GET THE RESEARCH

    Choose your license.

    Choose who needs access.
    All options are for this report and research series.

    Compare access permissions.

    Single User License
    One named user. Individual access.
    Multi User License
    Up to 5 users in the same department.
    Enterprise License
    Organization-wide access within the agreed license.

    Access applies to the purchased edition. Later editions are separate purchases.

    License options
    $4,950USD
    Buy now

    PDF by email within 3–5 working days after payment confirmation.

    Talk to an analyst
    APO Research
    Talk to an analyst